Printer Friendly

Can lessons from public health disease surveillance be applied to environmental public health tracking?

Disease surveillance has a century-long tradition in public health, and environmental data have been collected at a national level by the U.S. Environmental Protection Agency for several decades. Recently, the Centers for Disease Control and Prevention announced an initiative to develop a national environmental public health tracking (EPHT) network with "linkage" of existing environmental and chronic disease data as a central goal. On the basis of experience with long-established disease surveillance systems, in this article we suggest how a system capable of linking routinely collected disease and exposure data should be developed, but caution that formal linkage of data is not the only approach required for an effective EPHT program. The primary operational goal of EPHT has to be the "treatment" of the environment to prevent and/or reduce exposures and minimize population risk for developing chronic diseases. Chronic, multifactorial diseases do not lend themselves to data-driven evaluations of intervention strategies, time trends, exposure patterns, or identification of at-risk populations based only on routinely collected surveillance data. Thus, EPHT should be synonymous with a dynamic process requiring regular system updates to a) incorporate new technologies to improve population-level exposure and disease assessment, b) allow public dissemination of new data that become available, c) allow the policy community to address new and emerging exposures and disease "threads," and d) evaluate the effectiveness of EPHT over some appropriate time interval. It will be necessary to weigh the benefits of surveillance against its costs, but the major challenge will be to maintain support for this important new system. Key words: environmental health, evaluation, intervention, registries, surveillance. doi:10.1289/ehp.7450 available via[Online 2 December 2004]


The Centers for Disease Control and Prevention (CDC) describes its own mission as serving "as the national focus for developing and applying disease prevention and control, environmental health, and health promotion and education activities designed to improve the health of the people of the United States" (CDC 2005). Recently, the CDC, for the first time, funded state and larger metropolitan health departments and three academic centers to begin to develop a national environmental public health tracking (EPHT) network. The CDC vision for the EPHT program is to improve protection of communities from adverse health effects through the integration of public health and environmental information systems. To implement this vision, the goal is to develop a national tracking (i.e., surveillance) network that links chronic disease and environmental data sources.

Surveillance has a long tradition in public health for both the descriptive epidemiology of diseases and the provision of insights into disease causation and disease control. It can be taken as axiomatic that, ultimately, all surveillance systems aim at disease control. Generally, surveillance refers to the continuous, routine collection of data related to health or exposures of populations over the long term, and the associated analysis, interpretation, and dissemination of the results. Surveillance data collected by government agencies such as the CDC and the U.S. Environmental Protection Agency (EPA) provide important archives that permit continued reinterpretation and health research. To date, however, the data systems established and used for surveillance focus either on diseases/syndromes or on media (e.g., ambient air pollutants, toxic agents) without formal linkage between systems. In this article, we focus our analyses mainly on properties and lessons learned from disease surveillance systems. We also provide arguments that effective surveillance does not always require formal linkage of exposure and health outcome data; indeed, there are problems inherent in surveillance of environmentally related diseases when based on formal linkage of routinely collected data.

Established Surveillance Systems--History, Goals, and Properties

Surveillance for various specific diseases and toxic agents has become an established feature of public health systems in developed countries. The systems include sophisticated registries and monitoring networks that collect data through several different techniques.

The oldest systems that allowed monitoring of population health trends are vital statistic records established in Europe in the 1700s. In England and Wales, death records had a prominent place as demographic barometers for the health of communities and citizens throughout the 19th century. Variations in mortality rates from diseases such as cholera, dysentery, or workplace-related death (e.g., due to mining accidents) suggested socioeconomic, work-related, and environmental causes. This information was employed to justify a public health campaign not only to improve population health in England but also to measure the success of interventions [e.g., the construction of sewer systems (Mooney 1997)]. A distinguishing property of these early surveillance systems was a focus on acute causes of death for which there were either close temporal and/or spatial proximity between a perceived exposure and the outcome sufficient to establish causality (Koch, in press); or they allowed broad ecological comparisons of mortality rates between communities before and after public health interventions were implemented.

Vital statistics data (deaths, birth numbers, and outcomes) still provide a major source of surveillance data to monitor and to compare general trends in population health, to identify subgroups at risk, and to assess the effectiveness of intervention and treatment programs. Moreover, developed nations have invested in the establishment of many registry systems to collect more detailed morbidity data that provide surveillance for acute and chronic infectious diseases, occupational injuries and deaths, cancers, and birth defects. Unfortunately, in the United States none of the health outcomes surveillance databases are linked specifically, in either space or time, with relevant exposure databases.

Below we describe the function, motivation, and attributes that make these systems successful.

Surveillance for infectious and other acute diseases. Infectious disease surveillance is the paradigm for the surveillance of diseases that, aside from some exceptions (e.g., syphilis, tuberculosis, and AIDS), are characterized by acute onset and rapid resolution. The descriptive data provided by surveillance systems for these types of diseases provide the basis for the monitoring of the effects of interventions (e.g., standardized treatment, public education campaigns) and temporal and spatial trends that reflect changes in population behavior and attitudes, demography, provision of health services related to sexually transmitted diseases, and loss of efficacy of standard treatment regimens. The detection of "outbreaks" of disease [e.g., resurgence of syphilis in populations of homosexual males (D'Souza et al. 2003)] is an integral part of these systems. The timely collection, organization, analysis, and dissemination of these data facilitate prompt responses by public health systems to changes in disease occurrence for which immediate intervention appears warranted. The CDC's critical role in the control of infectious diseases depends, to a large extent, on data from these surveillance systems. For these efforts to succeed, highly specific and rapid methods for recognition and unambiguous diagnosis of diseases, coupled with effective and acceptable intervention strategies, must be available. Many acute infectious diseases fulfill these requirements. Continued technological advances can be expected to improve still further the diagnostic speed for other infectious diseases that require longer diagnostic confirmation periods, such as tuberculosis and AIDS. Intervention strategies to stop outbreaks are varied and include a) treatment of the infected individual, which results in both the recovery of the affected individual and the protection of susceptible individuals in the population from transmission, and b) if no treatment is available, quarantine of the infected individual until remission and immunization of susceptible individuals--that is, by prevention of transmission of the infectious agent and disease through the removal of susceptible individuals or carriers. Surveillance of diseases for which we routinely immunize continues for the purpose of identification of gaps in immunity in a population.

Infectious diseases of more insidious onset and/or tendency to relapse and remit over long periods of time (e.g., tuberculosis, HIV infection, malaria, Helicobacter pylori) pose problems for surveillance and characterize many of the chronic diseases that would be the target for environmental health tracking. Although the specific pathogens can be identified with relative ease, the diseases can present slowly over long periods, such that the connection between the primary exposure sources is lost or difficult to trace with specificity. Treatment usually is long and burdensome, and methods for primary prevention may be difficult or impossible to implement (in terms of cost, acceptability, and need for persistence). For example, to control malaria, one has to prevent transmission of the disease (vector control and behavior change) rather than control the disease after transmission has occurred. Because responses for these programs do not curb the occurrence of proximal cases, the success of these interventions will often not be apparent until after a lengthy period during which no new cases are observed. In fact, in cases where there are long delays between the implementation of an intervention and the reduction in disease incidence or morbidity, it may be difficult to quantitate precisely (or even accurately) the extent to which the intervention altered the outcome of the disease.

To complicate matters further, there are a number of infectious agents that, to date, elude our diagnostic and surveillance tools. Many viruses and bacteria cause nonspecific syndromes or symptom complexes that include most diarrheal and respiratory symptoms. The situation whereby similar syndromes are caused by many different infectious agents bears a striking similarity with the situation of environmental exposure to chemical agents because many different agents or mixtures can produce a similar syndrome. New infectious agents (and, by analogy, chemical exposures) that produce these nonspecific syndromes may elude detection for long periods or until such time as a unique syndrome has been successfully related to an agent/exposure (e.g., Escherichia coli O 157:H7c and hemolytic uremic syndrome). Although surveillance systems to monitor entire populations for these ubiquitous disease syndromes or symptoms that generally do not result in chronic illness or death have not been a priority in the past, the importance of "syndromic surveillance" has now been recognized (CDC 2004). Only when there is a small susceptible group that suffers severe symptoms or deaths do these syndromes start to draw public attention and require a response and investment in pathogen identification and disease prevention efforts (e.g., the West Nile virus outbreak; most infected individuals show minor symptoms of respiratory illness, but some infections in the elderly cause death). In general, for infectious diseases and syndromes for which we lack diagnostic and/or immunization-based prevention tools as a society, we opt for broad-based strategies to prevent exposure and intervene on potential media (e.g., prevention of contamination of water or food by microorganisms), instead of implementation of large disease- or syndrome-based surveillance.

Acute poisoning from metals or chemicals has similar attributes to infectious diseases, such as specific and acute symptom complexes that can be identified via biological tests. In the case of lead poisoning, state and federal agencies implemented a combination of preventive measures (removing lead from paint and gasoline) and surveillance for high levels of exposure that are likely in susceptible groups (e.g., in California for young low-income children with health insurance from Medi-Cal). However, there is one fundamental difference compared with the treatment of an infectious disease: Only lead removal from the environment, not the medical treatment of an individual, will reduce the risk to others in contaminated environments. Thus, the intervention that follows the identification of a poisoning case through surveillance will have to be broader and include remedial activities that remove the sources of poisoning. In fact, as we discuss below, the primary operational goal of environmental health tracking is the "treatment" of the environment in such a manner as to reduce population risk. Although a substantial part of the effort to control infectious diseases would also fall under this rubric, it is important to recognize that the individual medical treatment and prevention aspects of infectious disease surveillance are less relevant for many of the noninfectious health outcomes that will be considered for inclusion as part of environmental health tracking (e.g., asthma, many cancers).

Surveillance for chronic diseases. Similar to infectious and other acute disease surveillance, surveillance for chronic diseases has been implemented largely for diseases that are dreaded because of their consequences (disability and death). We define a chronic disease/syndrome as one that can have acute or insidious onset and whose symptoms and/or physiological abnormalities persist over long periods of time (years to lifelong, but they can remit with or without recurrence, e.g., asthma).

Another criterion that applies to both types of diseases for which surveillance systems exist is that they are identifiable by clinical and/or pathological examination with a high degree of specificity; that is, measurement tools are available and cost-effective and allow for unambiguous diagnosis. However, although early disease detection and intervention might be favorable and increase survival for some chronic diseases (e.g., carcinoma of the cervix, colon cancer, breast cancer), for many, neither screening tools nor universally effective treatments are available (e.g., lung cancer, many cancers of the gastrointestinal tract). Furthermore, because many chronic diseases generally are irreversible without some intervention, treatment interventions will not remove the cause of the disease in the same way as an antibiotic may eliminate bacteria and, at the same time, prevent transmission of the infection to others. However, in contrast to the specificity of metal chelation therapy in the case of lead poisoning, treatment for a chronic disease such as asthma is likely to be effective independent of the cause of the disease; for example, inhaled steroid treatment reduces inflammation and symptoms regardless of the nature of the trigger (molds, viruses, or air pollution) causing attacks.

Cancer surveillance has been described by CDC as an essential tool to a) assess patterns in the occurrence of cancer and detect important trends within populations, b) assess the impact of cancer prevention programs, and c) allow the rational allocation of limited resources for cancer (CDC 2004). Some of the attributes that favor certain infectious diseases for surveillance activities clearly overlap with those of certain cancers; that is, for some cancer types, effective strategies exist for reduction of mortality from cancer, and strategies for prevention of new cases may exist that include changes in behavioral and environmental factors.

Interestingly, another stated goal of cancer surveillance is the "wise allocation of limited resources including setting priorities for allocating health resources," which depends partly on the "availability of complete, timely, and high-quality cancer data" (CDC 2004). For those cancers for which the etiology is unclear and/or complex and/or for which satisfactory early screening tools and/or treatments are lacking, surveillance data represent an important research tool for ascertainment of disease etiology (host and environmental factors) and definition of disease natural history (progress of disease over time). For those cancers for which screening is new (e.g., recommendations for colonoscopy for colon cancer) or for which the groups that derive maximum benefit are still controversial (e.g., mammography), surveillance can provide important data on the effectiveness of screening. However, if there are long lag periods between the introduction of a screening procedure and improved survival for a specific cancer, it may be difficult to quantitate the population benefit. If a new environmental exposure or some human behavior intervenes during this time interval and changes the incidence and/or the natural history of a given cancer or group of cancers, the efficacy of a screening program may be underestimated at best or considered nonexistent at worst. These issues clearly are relevant for any environmental health tracking system that focuses on chronic health problems. These issues are summarized in Table 1.

The same caveat for new screening tools also applies to the evaluation of preventive interventions. Because of the long latency between initiation and diagnosis of most cancers, the effectiveness of preventive interventions, such as the success of smoking cessation programs, will not become apparent until years or even decades after implementation. Thus, intervention evaluation efforts must operate on a different time scale from those for many acute infectious diseases. Furthermore, cancers, like most chronic diseases, have multifactorial etiologies such that several risk factors operate through different or similar pathways that lead to the same outcome: For example, lung cancer can be caused by smoking and by exposure to asbestos, and subjects exposed to both agents may differ in risk from those exposed to either one of these carcinogens (Liddell 2001). However, surveillance of cancer trends over time that aims to document the success of an intervention could be misleading if the reduction of one of the carcinogens in a population (e.g., the prevalence of asbestos exposure) is accompanied by an increase in prevalence in another risk factor for the disease (e.g., smoking). Whether or not these two exposures would affect the same individuals in a population would not matter, because we are only monitoring trends in overall population rates.

Although cancer surveillance through registries enables a vast amount of etiologic research that contributes to the identification of cancer risk and preventive factors, this research is not part of the monitoring/surveillance effort per se but requires separately funded scientific studies, some of which will make use of surveillance data as a primary or major resource. These studies are necessary to identify the cancer-initiating events that generally precede disease diagnosis by years or decades and to estimate individual level exposures and take latency and susceptibility into account. Etiologic factors that contribute to cancers are not identifiable through disease surveillance except in those rare cases where a carcinogenic agent can be identified by a biological or chemical marker in the affected tissue(s) long after the initiation of cancer. One example is the human papilloma virus, which can be identified at higher rates in the tissue of women diagnosed with cervical cancer than among nonaffected controls (Salmeron et al. 2003). However in such cases, to permit causal inferences, a registry also would need to obtain samples from unaffected population controls, a task outside the scope of any registry. This reasoning extends also to cancer cluster investigations; that is, only when an etiology is already established and highly specific (e.g., for vinyl chloride and angiosarcoma or asbestos and mesothelioma, but not asbestos and lung cancer) can a cluster suggest the cause of the disease and be used to help guide intervention and prevention efforts (removal of asbestos). Therefore, careful consideration must be given to the expenditure of resources to investigate such occurrences.

Environmental Health Tracking

Use of existing surveillance systems for linkage purposes. We have listed the goals and requirements for an EPHT system in Table 2. Generally, such a system can take advantage of already existing, active, passive, or sentinel surveillance systems, if the requirements for linkage are fulfilled (see "System requirements," Table 2) or if they can be used as a starting point from which additional data that pertain to environmental exposures or the diseases of interest can be obtained. These systems have different functions, costs, and utility for public health and environmental tracking. Active surveillance systems have the advantage of relatively complete ascertainment and standardized collection of data over time but are very resource intensive and usually focused only on one type of disease or exposure. Passive systems are cheaper to maintain but are potentially subject to biased, incomplete reporting. Reports of unusual events (e.g., space-time clusters of disease, uncommon exposures such as a toxic spill) do not meet the formal requirements for surveillance noted above. However, the systems through which these reports appear (e.g., Morbidity and Mortality Weekly Report) do provide the temporal continuity and standardization of presentation that satisfy the requirements for surveillance. Reports of unusual events may provide the initial stimulus for the identification of important ongoing, environmental health risks but should avoid the pitfalls of chronic disease (cancer) cluster investigations. Most important, all existing surveillance systems, once they fulfill the requirements for linkage, can serve descriptive functions and allow the conduct of ecologic analyses in the broadest sense--that is, population exposures and outcomes for population inference. On the other hand, etiologic questions may be answerable only if additional resources become available to a) provide for collection of additional data for assessment of exposure and other disease risk factors (e.g., those that act as confounders or effect modifiers) at the individual level (e.g., pesticide or air pollution exposures at homes and workplaces of subjects of interest, smoking and diet information, genetic susceptibility factors, access to health care); b) collect data in control subjects (e.g., nondiseased subjects as controls for cancers) or collect data for diseases for which routine monitoring systems are not in place (e.g., asthma); and c) conduct additional data analysis not provided for within the routine monitoring systems. Furthermore, certain etiologic questions may be answered best through other types of study design that do not rely on disease monitoring in a geographically based population but either follow cohorts of individuals over a long time [e.g., Nurses' Health Study (Hunter et al. 1990; Laden et al. 2001) cohort] and/or store biological samples for a large number of individuals [e.g., the National Health and Nutrition Examination Survey (NHANES) (Chapman et al. 2003)], or target special highly exposed groups within a population [e.g., the Agricultural Health Study for pesticide exposures (Alavanja et al. 2003)] or vulnerable subgroups of a population (children for asthma, elderly for Alzheimer or Parkinson disease). Table 3 lists the advantages and disadvantages of different systems to evaluate environmental health questions and references examples from the literature for the use of such systems.

Criteria for the expansion/contractions of an existing surveillance system. The design of an EPHT and surveillance system cannot be static. There always will be a need to expand the "core" of the system or to provide ad hoc elements to address specific issues whether these relate to what data the system collect or which populations it needs to cover. The criteria for expansion (and contraction) cannot be specified a priori; however, what can be specified is a process to keep the system dynamic and relevant. Table 4 summarizes some suggested questions that should be addressed. Most important are recognition of the need for continued re-evaluation and the existence of a base of fiscal resources to make adjustments when such are deemed necessary.

A parallel issue relates to the ability of a tracking system to recognize the potential for some new environmental exposure to cause health effects before adequate human health data are available. The solution to this problem is the inclusion of a mechanism for ongoing, continuing reviews of the relevant toxicology and exposure literature. The regular preparation of position papers by expert panels should serve as the first step in the decision-making process that is identified by item 1 in Table 4. The findings of these position papers should be subjected to a second-level review to assess the logistical and cost-benefit implications of the inclusion of new exposures into the tracking system.

Conclusions and Recommendations

Initiation of linkage between existing disease and exposure surveillance systems for EPHT is very desirable and feasible. We have identified what we believe to be the important pitfalls that should be avoided for such linkage activities. The goals, purposes, and limitations of any proposed linkage must be discussed and stated clearly. In addition, currently available data resources and surveillance systems will need to be evaluated critically first to decide whether they fit the criteria for a successful linkage or might need to be updated and expanded to make linkage possible and useful.

Identification of many important relations between environmental factors and heath outcomes requires individual-level data that are not routinely collected by any surveillance system; thus, these can be addressed adequately only with targeted research. In contrast, data linkages performed in a surveillance context typically will not be able to address key factors at the level of the individual. Data linkage efforts may be able to detect some relations but would also be expected to miss others that could, however, be established in well-designed epidemiological studies. The distinction between data linkages in the surveillance context and targeted research is an important one, and the EPHT program must avoid the expectation that simple linkage approaches in the surveillance context can substitute for sound epidemiological research.

Design of surveillance approaches requires a balance between demands for more extensive and higher quality data and the feasibility of collecting such data. For environmental agent--disease relationships that are already well established, formal linkage of data may not be the most efficient use of resources. For example, exposure to lead has been clearly associated with decreased cognitive development in children. Use of data linkage projects to assess this relationship at the community level might be problematic because of our potential inability to detect subtle but important effects that require large cohorts of children and very sophisticated test procedures, and resources might be better devoted to identifying and addressing determinants of exposure. Furthermore, tracking of exposures to environmental agents without linkage to health outcomes can spawn effective interventions, such as efforts to reduce the use of polybrominated diphenyl ethers after these compounds were detected in increasing concentration over time in human breast milk.

Concerns about the implications of data linkage are particularly important in a policy context. A community-level association between exposure to an environmental hazard and an adverse health outcome need not be demonstrated before intervention is initiated if the relationship has been appropriately established in the scientific literature. For example, not every community needs to show a relationship between consumption of local fish contaminated with mercury and elevated blood mercury levels before taking action to warn the population that excessive local fish consumption should be avoided. Moreover, as we discussed above, for chronic diseases of multifactorial etiology, it will be difficult to demonstrate relationships between reductions in releases or concentrations of environmental agents and disease outcomes. The U.S. EPA is beginning to emphasize "accountability"--that is, demonstrations that reductions in health outcomes result from policy activities that reduce levels of hazardous agents in the environment. Although it is laudable to show such relationships where they can be demonstrated, the converse view that such relationships must be demonstrated before a policy intervention can be initiated is not supported.

Because chronic, multifactorial diseases do not lend themselves to data-driven, quick, and convenient evaluations of intervention strategies, time trends, exposure identification, or the identification of at-risk populations based on linkage and surveillance only, we propose that, first and foremost, EPHT should be synonymous with a dynamic process that requires regular system updates to a) incorporate new technologies to improve exposure and disease assessment at the population level, b) allow public dissemination of new data that become available, c) allow the public health and environmental policy communities to address new and emerging "threads" (for both exposures and health outcomes), and d) evaluate its effectiveness over some appropriate time interval. A challenge will be to maintain consistent support and funding for important routine public health systems that may seem less exciting than the public outrage producing "toxins or diseases of the week." This is particularly true at times of economic downturns, in response to short-term public and political pressures. Although the risks attributable to environmental factors might be small in a relative sense, they can result in a large disease burden in absolute numbers because of the ubiquitous nature of certain exposures, the possible synergy of these factors with other risk factors, and the increased vulnerability of certain subpopulations. Thus, risk assessments based on any single surveillance system are likely to provide downwardly biased estimates of risk for a specific environmental hazard, because of the difficulty related to the identification of the effects of exposures to multiple environmental hazards whose composition may change over time and for which it is nearly impossible to construct accurate exposure histories even at an ecological level. Nonetheless, in some cases, surveillance may be the only practical method to obtain sufficient data to carry out a preliminary assessment of risk (contingent on adequate quality data).

By their nature, many chronic diseases are irreversible to a large extent (if at all) even after the exposure is removed. Therefore, treatment interventions directed at individuals will not remove the cause of the disease or the possible source of disease for others in the community. Thus, the primary operational goal of environmental health tracking has to be the "treatment" of the environment in such a manner as to reduce population risk. It will be important and necessary to evaluate and weigh the benefits of surveillance against its costs. In addition, we have pointed out that some strategies to evaluate the effectiveness of interventions can be severely flawed if they do not address the complexity of disease causation. On the other hand, prevention might be our only rationale option, even if multifactorial diseases do not lend themselves to surveillance data-driven evaluations of intervention strategies.
Table 1. Challenges for chronic disease
surveillance relevant to EPHT.

Characteristics of the disease
 Onset can be insidious
 Exact time of onset not known and often not subject to
 estimation, which complicate temporal characteristics
 of exposure
 Often long latency between onset of exposure and clinical
 manifestation of disease
 Heterogeneous mix of phenotypic components (e.g., asthma: allergic,
 nonallergic, cough variant types)
 May have multiple natural histories and differ in antecedent
 exposure profiles (risk factors for onset or recurrence)
 Genetic heterogeneity may not be reflected in phenotype
 (e.g., young-onset breast cancers with and without BRCA1
 and BRCA2 mutations)
 Multiple etiologies; some pathways may not involve the same
 putative risk factors (e.g., young-onset Parkinson
 disease caused by MPTP exposure or by Parkin mutations)
 Characteristics of exposure
 Often involves complex mixtures that can change over time
 Relevant parameters often not easily defined
 Timing of onset
 Cumulative dose versus critical time of exposure
 Threshold versus no threshold
 Effect modification by other exposures
 Direct measurement often not available
 Reliance on imperfect surrogates

MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Table 2. Goals and requirements for an EPHT system.

Surveillance Requirements for Requirements for
goals health data exposure data

Descriptive Chronic diseases Long-term exposure
 (ecologic) Specificity of assessment
 Temporal diagnosis Broad spatial coverage
 Spatial Standardization of that captures medium-
 diagnostic algorithms scale spatial
 over time and heterogeneity and
 procedures to convert should "match" health
 from one standard to spatial units as
 another (e.g., ICD-9 closely as possible
 to ICD-10) Long historical record
 Moderately short time keeping and
 delays between acceptable procedures
 diagnosis and to convert old to new
 "registration" (e.g., measurement
 example within 6 techniques or metrics
 months) Develop criteria for
 Agreed upon spatial selection of
 reference (e.g., exposures such as
 residence at known or suspected
 diagnosis) health impacts and/or
 Acute diseases (e.g., regulatory
 poisonings) requirements
 Specificity of Identification of
 diagnosis "sentinel" substances
 Standardization of where possible
 diagnostic algorithms Collect data on
 over time and Broad categories of
 procedures to convert sources
 from one standard to Broad classes of
 another (e.g., ICD-9 relevant "components"
 to ICD-10)
 Short time delay
 identification and
 (e.g., days to weeks)
 Agreed upon spatial
 reference (e.g.,
 residence at

Etiologic Chronic and acute Requirements in addition
 Chronic diseases and clusters to those mentioned
 Acute Specificity and above
 Clusters standardization (as Near real-time or real-
 (spatial needed for time access to
 and descriptive purposes) quality-assured data
 temporal) Time of registration for acute disease and
 and spatial reference cluster evaluation
 (as above) Ability to estimate
 Expanded data on risk individual exposure
 factors for acute, cluster
 Access to noncases for and chronic disease,
 risk factors and or refined spatial
 exposure and temporal data for
 acute disease and
 cluster evaluation
 Data sufficient for
 spatial and temporal
 (acute and
 cumulative) exposure
 modeling over time
 for chronic disease
 Specific source
 apportionment in
 terms of sources and
 components for acute
 disease and cluster

goals System requirements

Descriptive Minimum set of variables for linkage
 (ecologic) is available (e.g., residential/work
 Temporal address and geocoded exposure
 Spatial location)
 Clear documentation of all variable
 fields, including documentation of history
 of changes in format and/or content
 Continued linkage of health and
 exposure data
 Continued dissemination of results
 to agencies and public
 Ongoing administrative, legal, and
 fiscal support for linkage and
 dissemination activities

Etiologic Requirements in addition to those
 Chronic mentioned above
 Acute Ability to acquire QA/QC and
 Clusters release data consistent with time
 (spatial requirements
 and Ability to support special monitoring
 temporal) projects
 Fiscal and staff support for ongoing
 Fiscal support for selected, existing
 registries and special studies

Abbreviations: ICD, International Classification of Diseases, 9th
and 10th Revisions (WHO 1978, 1993); QA/QC, quality assurance/
quality control.

Table 3. Advantages and disadvantages of various systems for the
examination of environmental health questions.

Registries Advantages

Disease registries
 Death or birth Standardized continuous collection of data
 certificates for the total population in a geographic area
 Collects causes of deaths, birth weight, and
 gestational age in a standardized manner
 Allows examination of differences in space
 and time that includes trends for causes of
 deaths and birth outcomes
 Relatively cheap and well established

Disease registries Standardized continuous collection of data
 (reportable for the total or subgroups of a population in
 infectious a geographic area
 diseases, Allows examination of differences in space and
 cancer, end- time that includes trends for these diseases
 stage renal High-data quality for registries established
 disease, and in accordance with specified (national)
 birth defect standards (e.g., surveillance epidemiology
 registries; and end results cancer registry standards)
 discharge data;

 Ecological Standardized continuous collection of exposure
 exposure data for the total population in a
 registries/ geographic area
 databases (air Allows examination of differences in
 and water space and time that includes trends for
 pollution, these exposures
 pesticides, High-data quality for these registries based
 industrial upon certain specified (national) standards
 emissions Allows for population-level exposure
 inventories) estimates either directly or through model

Individual-level Collects specific exposure data for a group
 exposure of select individuals suspected to be
 registries exposed at high levels, or for a regional or
 (biomonitoring, national random sample of the population
 e.g., NHANES) Allows examination of exposure differences
 in space and time that includes trends for
 exposures if collected repeatedly or
 Individual-level exposure measurements available
 Specific exposures of relatively high data

 Cross-sectional Collect data on one or more diseases and
 or repeated exposures simultaneously for a representative
 surveys regional, national, or international sample
 (NHANES, using standardized methods
 ISAAC, MONICA, Allows examination of differences in space and
 CHIS) time including trends for exposures and
 diseases if collected repeatedly
 Individual-level exposure and disease measures
 High-data quality
 Subjects need to be contacted and participate
 only once

 Longitudinal Collect one or more diseases and exposures
 cohorts over time
 (Framingham Longitudinal data for exposure and disease
 study, Nurses' avoid problems of temporal ambiguity
 Health Study, Investigation of outcomes beyond those of
 California original interest often can be undertaken
 Teachers Individual-level exposure estimates available
 Study, High-data quality
 Health Study)

Registries Disadvantages references

Disease registries
 Death or birth Outcome data are relatively Ritz et al.
 certificates limited in breadth (i.e., to 2000
 fatal diseases and few birth Wilhelm and
 outcomes) Ritz 2003
 Relatively little quality
 control over data collection
 No exposure data
 Automatic link to exposure data
 possible through address
 (at birth or deaths)
 For extensive individual level
 exposure assessment, subjects
 (or proxies) need to be
 contacted (additional research
 funding necessary)
 Potential ethical and legal
 concerns related to automatic
 data linkage

Disease registries Laws necessary that mandate Ritz et al.
 (reportable reporting and registration 2002
 infectious Continuous and extensive Reynolds et
 diseases, financial support necessary al. 2003
 cancer, end- Often registers only one Shaw et al.
 stage renal specific type of disease 1999
 disease, and No exposure data available Mann et al.
 birth defect Automatic link to exposure data 2002
 registries; possible through address at
 hospital diagnosis (additional research
 discharge data; funding necessary)
 health Potential ethical and legal
 maintenance concerns related to automatic
 organization data linkage

 Ecological Laws necessary that mandate Ritz and Yu
 exposure reporting and registration 1999
 registries/ Continuous and extensive Mortimer et
 databases (air financial support necessary al. 2002
 and water Usually registers only one
 pollution, specific type or group
 pesticides, of exposures in a single
 industrial medium (e.g., air, water)
 emissions Exposure data are collected at
 inventories) the ecological not at the
 individual level
 No disease information without
 additional linkage to
 geographic identifiers (e.g.,
 For disease outcome, linkage
 subjects (or proxies) may need
 to be contacted (additional
 research funding necessary)

Individual-level Very expensive Murphy et
 exposure Usually only one type of al. 1983
 registries specific exposure collected MacIntosh et
 (biomonitoring, Usually no disease data al. 1996
 e.g., NHANES) collected simultaneously or Ruckart et
 prospectively (needs addition al. 2004
 research funding)
 If samples are collected for
 specific research purposes
 only, subjects need to consent
 to new analyses
 Groups that are willing to
 contribute urine, blood,
 etc., may not be
 representative of the larger

 Cross-sectional One time or repeated high Keil et al.
 or repeated financial investment 1996
 surveys necessary; costs depend on Hirsch et al.
 (NHANES, data collection protocol, 1999
 ISAAC, MONICA, sample size, length of Ramadour et
 CHIS) observation period, etc. al. 2000
 Cross-sectional data for Peters et al.
 exposure and disease may cause 2001
 problems of temporal ambiguity Chapman et al.
 and survivor bias 2003
 Disease outcome measures often
 rely on self-report only
 Research subjects have to be
 willing to participate, thus
 may not be representative of
 the general population

 Longitudinal Extremely high financial Hunter et
 cohorts investment necessary over al. 1990
 (Framingham extended periods, costs depend Garland et al.
 study, Nurses' on data collection protocol, 1995
 Health Study, sample size, length of Feskanich et
 California observation period, etc. al. 1998
 Teachers A cohort is by definition a Laden et al.
 Study, restricted group of 1999, 2001
 Agricultural individuals that may or may Alavanja et
 Health Study) not be representative of a al. 2003
 population of specific
 interest (e.g., those highly
 exposed to an environmental
 agent or those within a
 susceptible age or ethnicity)
 Research subjects have to be
 willing to participate
 repeatedly over extended
 periods of time and have to be
 The study protocol dictates
 exactly for which disease and
 exposures information will be
 collected, unless biological
 samples can be stored for
 later analyses (which may have
 legal implications for

Abbreviations: CHIS, California Health Interview Survey; ISAAC,
International Study of Asthma and Allergies in Childhood; MONICA,
Monitoring of Trends and Determinants in Cardiovascular Diseases.

Table 4. Issues for expansion and contraction of an EPHT system.

1. Have scientific data provided compelling new evidence of
disease--exposure associations or evidence that previously suspected
associations are not causal?

2. Are there new technologies (biomarkers, molecular dosimeters) that
indicate the need to updated data collection procedures?

3. Have there been changes in nesology that require new
case definitions?

4. Are there new sources of ongoing data collection (routine
public health, research cohorts) that offer cost-efficient
opportunities to expand surveillance activities?

5. Have there been changes to sources of exposure data that either
improve their quality or render them no longer suitable for routine

6. Is there public concern about an environmental health issue for
which surveillance is the most efficient mechanism to acquire
preliminary data?

7. Is there widespread use of a new substance/chemical with the
potential for exposing a large population or biopersistence of
a substance (e.g., phthalates)?

We thank J. Mann for her comments and all members of the Center for Excellence in Environmental Public Health Tracking for their involvement in discussions of some of the issues presented here.


Alavanja MC, Samanic C, Dosemeci M, Lubin J, Tarone R, Lynch CF, et al. 2003, Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort. Am J Epidemiol 157(9):800-914.

Chapman RS, Hadden WC, Perlin SA. 2003. Influences of asthma and household environment on lung function in children and adolescents: the Third National Health and Nutrition Examination Survey. Am J Epidemiol 158(2):175-189.

CDC. 2004. National Program of Cancer Registries: The Foundation for Cancer Prevention and Control. Atlanta, GA:National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. Available: about2004.htm [accessed 21 November 2004].

CDC. 2005. About CDC. Atlanta, GA:Centers for Disease Control and Prevention. Available: [accessed 22 January 2005].

D'Souza G, Lee JH, Paffel JM. 2003. Outbreak of syphilis among men who have sex with men in Houston, Texas. Sex Transm Dis 30(12):872 873.

Feskanich D, Owusu W, Hunter DJ, Willett W, Ascherio A, Spiegelman D, et al. 1998. Use of toenail fluoride levels as an indicator for the risk of hip and forearm fractures in women. Epidemiology 9(4):412-416.

Garland M, Morris JS, Stampfer M J, Colditz GA, Spate VL, Baskett CK, et al. 1995. Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 87(7):497-505.

Hirsch T, Weiland SK, von Mutius E, Safeca AF, Grafe H, Csaplovics E, et al. 1999. Inner city air pollution and respiratory health and atopy in children. Eur Resp J 14(3):669-877.

Hunter DJ, Morris JS, Stampfer MJ, Colditz GA, Speizer FE, Willett WC. 1990. A prospective study of selenium status and breast cancer risk. JAMA 264(9):1128-1131.

Keil U, Weiland SK, Duhme H, Chambless L. 1996. The International Study of Asthma and Allergies in Childhood (ISAAC): objectives and methods; results from German ISAAC centres concerning traffic density and wheezing and allergic rhinitis. Toxicol Lett 86(2 3):99-103.

Koch T. In press. The map as intent: variations on the theme of John Snow. Cartographica.

Laden F, Hankinson SE, Wolff MS, Colditz GA, Willett WC, Speizer FE. 2001. Plasma organochlorine levels and the risk of breast cancer: an extended follow-up in the Nurses' Health Study. Int J Cancer 91(4):568-574.

Laden F, Neas LM, Spiegelman D, Hankinson SE, Willett WC, Ireland K, et al. 1999. Predictors of plasma concentrations of DDE and PCBs in a group of U.S. women. Environ Health Perspect 107:75-81.

Liddell FDK. 2001. The interaction of asbestos and smoking in lung cancer. Ann Occup Hyg 45:341-356.

MacIntosh DL, Spengler JD, Ozkaynak H, Tsai L, Ryan PB. 1996. Dietary exposures to selected metals and pesticides. Environ Health Perspect 104:202-209.

Mann JK, Tager IB, Lurmann F, Segal M, Quesenberry CP Jr, Lugg MM, et al. 2002. Air pollution and hospital admissions for ischemic heart disease in persons with congestive heart failure or arrhythmia. Environ Health Perspect 110:1247-1252.

Mooney G. 1997. Professionalization in public health and the measurement of sanitary progress in nineteenth-century England and Wales. Soc Hist Med 10(1):53-78.

Mortimer KM, Neas LM, Dockery DW, Redline S, Tager IB. 2002. The effect of air pollution on inner-city children with asthma. Eur Respir J 19(4):699-705.

Murphy RS, Kutz FW, Strassman SC. 1983. Selected pesticide residues or metabolites in blood and urine specimens from a general population survey. Environ Health Perspect 48:81-86.

Peters A, Frohlich M, Doring A, Immervoll T, Wichmann HE, Hutchinson WL, et al. 2001. Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. Eur Heart J. 22(14):1198-1204.

Ramadour M, Burel C, Lanteaume A, Vervloet O, Charpin D, Brisse F, et al. 2000. Prevalence of asthma and rhinitis in relation to long-term exposure to gaseous air pollutants. Allergy 55(12):1163-1169.

Reynolds P, Von Behren J, Gunier RB, Goldberg DE, Hertz A, Harnly ME. 2003. Childhood cancer and agricultural pesticide use: an ecologic study in California. Environ Health Perspect 110:319-324.

Ritz B, Yu F. 1999. The effect of ambient carbon monoxide on low birth weight among children born in Southern California between 1989 and 1993. Environ Health Perspect 107:17-25.

Ritz B, Yu F, Chapa G, Fruin S. 2000. Effect of air pollution on preterm birth among children born in Southern California between 1989 and 1993. Epidemiology 11:502-511.

Ritz B, Yu F, Chapa G, Fruin S, Shaw G, Harris J. 2002. Ambient air pollution and birth defects. Am J Epidemiol 155:17-25. Rothman K. 1986. Modern Epidemiology. Boston:Little Brown & Co.

Rothman K. 1990. A sobering start for the cluster busters' conference. Keynote presentation. Am J Epidemiol 132(suppl 1):S6-S13.

Ruckart, PZ, Kakolewski K, Bove FJ, Kaye WE. 2004. Long-term neurobehavioral health effects of methyl parathion exposure in children in Mississippi and Ohio. Environ Health Perspect 112:46-51.

Salmeron J, Lazcano-Ponce E, Lorincz A, Hernandez M, Hernandez P, Leyva A, et al. 2003. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 14(6):505-512.

Shaw GM, Wasserman CR, O'Malley CD, Nelson V, Jackson RJ. 1999. Maternal pesticide exposure from multiple sources and selected congenital anomalies. Epidemiology 10(1):60-66.

WHO. 1978. International Classification of Diseases, 9th Revision. Geneva:World Health Organization.

WHO. 1993. International Classification of Diseases, 10th Revision. Geneva:World Health Organization.

Wilhelm M, Ritz B. 2003 Residential proximity to traffic and adverse birth outcomes in Los Angeles County, California, 1994-1996. Environ Health Perspect 111:207-116.

Beate Ritz, (1) Ira Tager, (2) and John Balmes (3)

(1) Department of Epidemiology, University of California, Los Angeles, California, USA; (2) Division of Epidemiology, and (3) Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, California, USA

Address correspondence to B. Ritz, Department of Epidemiology, University of California at Los Angeles, 650 Charles Young Dr., Room 73-320 CHS, Los Angeles, CA 90095 USA. Telephone: (310) 206-7458. Fax: (310) 206-6039. E-mail:

This work was partially funded by a Centers for Disease Control and Prevention grant for a Center of Excellence for Environmental Public Health Tracking at the University of California at Los Angeles, University of California at Berkeley, and University of California at San Francisco, grant U50/CCU922409-03.

Received 27 July 2004; accepted 2 December 2004.
COPYRIGHT 2005 National Institute of Environmental Health Sciences
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Commentary
Author:Balmes, John
Publication:Environmental Health Perspectives
Date:Mar 1, 2005
Previous Article:Choosing safe fish: too little data on the menu.
Next Article:Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic.

Related Articles
Environmental pesticide illness and injury: the need for a national surveillance system.
Developing a local comprehensive environment and health tracking system: using what we know to improve health and the environment.
The application of the Haddon matrix to public health readiness and response planning.
National Environmental Public Health Tracking Program: bridging the information gap.
Developing a comprehensive pesticide health effects tracking system for an urban setting: New York City's approach.
Tracking pediatric asthma: the Massachusetts experience using school health records.
Wisconsin's environmental public health tracking network: information systems design for childhood cancer surveillance.
Integrated assessment of environment and health: America's children and the environment.
Integrating research, surveillance, and practice in environmental public health tracking.
Children's health/regional collaboration to reduce lead exposure in children.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters